Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $19,525 | $20,904 | $26,495 | $18,461 |
| % Growth | -6.6% | -21.1% | 43.5% | – |
| Cost of Goods Sold | $2,662 | $3,001 | $7,842 | $2,248 |
| Gross Profit | $16,863 | $17,903 | $18,653 | $16,213 |
| % Margin | 86.4% | 85.6% | 70.4% | 87.8% |
| R&D Expenses | $11,104 | $11,359 | $12,214 | $11,168 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11,313 | $13,087 | $12,375 | $13,613 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22,417 | $24,446 | $24,589 | $24,781 |
| Operating Income | -$5,604 | -$6,543 | -$5,936 | -$8,568 |
| % Margin | -28.7% | -31.3% | -22.4% | -46.4% |
| Other Income/Exp. Net | $2,372 | $1,352 | -$1,606 | $1,916 |
| Pre-Tax Income | -$3,232 | -$5,191 | -$7,542 | -$6,652 |
| Tax Expense | $7 | $5 | -$752 | $346 |
| Net Income | -$3,239 | -$5,196 | -$6,790 | -$6,998 |
| % Margin | -16.6% | -24.9% | -25.6% | -37.9% |
| EPS | -0.072 | -0.12 | -0.15 | -0.16 |
| % Growth | 40.4% | 20% | 6.3% | – |
| EPS Diluted | -0.072 | -0.12 | -0.15 | -0.16 |
| Weighted Avg Shares Out | 45,318 | 45,104 | 44,875 | 44,627 |
| Weighted Avg Shares Out Dil | 45,318 | 45,104 | 44,875 | 44,627 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1,352 | -$1,606 | $1,916 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $71 | $102 | $121 |
| EBITDA | -$5,604 | -$5,120 | -$5,834 | -$8,447 |
| % Margin | -28.7% | -24.5% | -22% | -45.8% |